InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,180.74
(
1.03%
)
US TECH 100
17,598.80
(
1.03%
)
Dow Jones
38,852.27
(
0.46%
)
Brent Oil
83.43
(
-0.05%
)
Bitcoin
63,209.78
(
0.07%
)
Post# of 251732
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 827
Posts 119581
Boards Moderated 14
Alias Born 09/05/2002

DewDiligence

Member Level

Re: semi_infinite post# 240770

Monday, 12/13/2021 11:22:26 AM

Monday, December 13, 2021 11:22:26 AM

Post# of 251732
ABUS inks Greater-China* development deal for AB-729—$40M up-front cash:

https://finance.yahoo.com/news/arbutus-qilu-pharmaceutical-enter-exclusive-123000244.html

AB-729, an injected RNAi agent that targets HBsAg (HBV surface antigen), is a drug candidate I’ve been generally unimpressed with (e.g. #msg-164615657).

However, the most notable aspect of the above deal (IMO) is that it does not include AB-806, ABUS’ core inhibitor (#msg-167079537).

*China, Hong Kong, Macau, Taiwan.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up